Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Mayo Clin Proc. 2015 Dec 8;91(1):71–80. doi: 10.1016/j.mayocp.2015.10.018

Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention Among Postmenopausal Women

Aditya Bardia 1, Tanya E Keenan 1, Jon O Ebbert 1, DeAnn Lazovich 1, Alice H Wang 1, Robert A Vierkant 1, Janet E Olson 1, Celine M Vachon 1, Paul J Limburg 1, Kristin E Anderson 1, James R Cerhan 1
PMCID: PMC4807132  NIHMSID: NIHMS767195  PMID: 26678006

Abstract

Objective

To better understand the potential risk/benefit ratio for targeted chemoprevention, we evaluated the association of aspirin and other NSAIDs with incidence of postmenopausal breast cancer for risk subgroups defined by selected non-modifiable or difficult-to-modify breast cancer risk factors.

Patients and Methods

Postmenopausal women with no history of cancer on July 1, 1992 (N=26,580) were prospectively followed through December 31, 2005 for breast cancer incidence (N=1581). Risk subgroups were defined on family history of breast cancer, age at menarche, age at menopause, parity/age at first live birth, history of benign breast disease, and body mass index (BMI). Hazard ratios (HRs) and 95% confidence intervals (CIs) adjusted for other breast cancer risk factors were estimated using Cox models.

Results

Aspirin use was associated with a lower incidence of breast cancer for women with family history of breast cancer (HR=0.62 for 6+ per week vs. never use; 95%CI 0.41-0.93) and personal history of benign breast disease (HR=0.69; 95%CI 0.50-0.95), but not for women in higher risk subgroups for age at menarche, age at menopause, parity/age at first live birth or BMI. In contrast, inverse associations with aspirin use were observed in all lower risk subgroups. NSAID use had no association with breast cancer incidence.

Conclusion

Based on their increased risk of breast cancer, postmenopausal women with a family history of breast cancer or a history of benign breast disease could potentially be targeted for aspirin chemoprevention studies. Future studies are needed to confirm these findings.


Breast cancer is the most common non-cutaneous cancer and the second leading cause of cancer-related death among women in the United States.1 In 2015, an estimated 231,840 new cases of invasive breast cancer will be diagnosed among women and over 40,000 women will die of breast cancer.2 Furthermore, one in eight women in the U.S. will develop invasive breast cancer during their lifetime.2 Thus, effective breast cancer prevention strategies, particularly among higher risk women, could have tremendous public health impact.

Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) have been extensively investigated as potential cancer chemopreventive agents.3-8 NSAIDs may inhibit tumor growth by modulating cellular proliferation and apoptosis, predominantly via suppression of endogenous production of prostaglandin from inhibition of cyclooxygenase (COX) enzyme activity, particularly COX-2, which is over-expressed in cancer.9-13 NSAIDs can also inhibit aromatase, a critical enzyme involved in endogenous production of estrogens in postmenopausal females.14 Most15-26 but not all27-30 epidemiologic studies have observed an inverse association of either aspirin or other NSAIDs with breast cancer risk, including an earlier report from this cohort.31

Despite the consistent epidemiological observation, a causal association between aspirin and breast cancer has not been proven in randomized controlled trials, so it is not used in clinical practice as a chemopreventive agent. Furthermore, potential adverse effects, such as gastrointestinal bleeding and cerebral hemorrhage,6,32 currently outweigh any putative benefits in the setting of breast cancer prevention in the general population. However, the risk-benefit ratio might be different for postmenopausal women at higher risk of breast cancer than those at average or lower risk, particularly based on non-modifiable factors, such as family history of breast cancer, history of benign breast disease, reproductive history (age at menarche, age at menopause, parity and age at first live birth), or difficult to modify risk factors such as body mass index (BMI). “Personalizing” aspirin use to target specific higher risk groups might be more broadly accepted for clinical trials and in clinical practice than universally treating all postmenopausal women with aspirin. Using a population-based cohort, we evaluated the association of aspirin and non-aspirin NSAIDs with breast cancer risk among postmenopausal women within risk subgroups defined by individual and total number of selected non-modifiable or difficult-to-modify risk factors.

Methods

Iowa Women's Health Study (IWHS) Cohort

The IWHS is a prospective cohort study of postmenopausal women aged 55–69 years at study baseline in 1986.31,33 Briefly, in 1986 a 16-page questionnaire was mailed to 98,030 randomly selected women in Iowa based on drivers' license, and was returned by 41,836 women (42.7%) who constituted the original cohort. Compared to non-respondents, respondents were on average 3 months younger, had a 0.4 kg/m2 lower body mass index, and were more likely to live in rural areas. The non-respondents have been demonstrated to have a slightly higher mortality rate due to smoking-related diseases compared to respondents.34 Follow-up questionnaires (response rates) were conducted in 1987 (91%), 1989 (90%), 1992 (83%), 1997 (79%), and 2004 (70%).

Risk Factors of Interest

On the baseline survey (1986), information was collected on age, marital status, level of education, height, weight, age at menarche, age at menopause, number of live births, age at first live birth, family history of breast cancer, use of oral contraceptives or hormone therapy, physical activity, history of benign breast disease, history of cigarette smoking, alcohol consumption, and history of rheumatoid arthritis or osteoarthritis. The use of aspirin and non-aspirin NSAIDs in the cohort was ascertained on the 1992 follow-up questionnaire. Participants were asked, “How often do you take aspirin? Examples of aspirin include Bufferin, Anacin, enteric-coated aspirin, Ecotrin, and Excedrin (Do not include acetaminophen, Tylenol, Ibuprofen, Advil): never, less than one per week, one per week, 2–5 per week, and 6+ per week. ” Use of non-aspirin NSAIDs was queried as, “How often do you take other nonsteroidal anti-inflammatory drugs or arthritis medicines? Examples include Ibuprofen, Advil, Nuprin, Motrin, Naprosyn, Feldene, and Clinoril (Do not include aspirin, acetaminophen, Tylenol, prednisone, cortisone, Deltasone): never, less than one per week, one per week, 2–5 per week, and 6+ per week. ”

Based on current literature, we defined a priori the non-modifiable or difficult-to-modify breast cancer risk factors (and respective cutpoints) for postmenopausal women as age at menarche <11 years; age at menopause ≥55 years; nulliparous or age at first live birth >30 years; BMI of ≥30 kg/m2; any family history of breast cancer in a first degree relative; and history of benign breast disease. BMI ≥30 kg/m2 (the WHO definition of obesity) was included because it is relatively difficult to modify in older women. All of these factors have consistently been reported to be associated with risk of breast cancer, including recent pooled results from 35,568 breast cancer patients from 34 studies,35 and many are also included in the Gail model for breast cancer risk,36 for which we did not have individual elements.

Cohort Follow-Up

Incident breast cancers were identified through 2005 by linking the cohort to the Iowa Cancer Registry, a member of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program.37 Cohort members were matched against registry files according to name, maiden name, zip code, birth date, and social security number. Deaths were identified through annual linkage to Iowa state death certificates, supplemented by linkage to the National Death Index. Estrogen and progesterone receptor status of the tumor was obtained from registry records.38

Data Analysis

Among 41,836 participants, women were excluded if they were premenopausal at enrollment in 1986 (n=569); had a diagnosis of cancer (excluding nonmelanoma skin cancer) at the 1986 baseline (n=3830) or at the 1992 follow-up (n=2949); had a total or partial mastectomy (n=1884); did not return the 1992 follow-up questionnaire due to death or non-response (n=8819); or skipped the aspirin or NSAIDs questions (n=681). After exclusions, 26,580 women remained in the at-risk cohort (exclusions were not mutually exclusive).

Follow-up for each woman began on July 1, 1992, the approximate date of the 1992 questionnaire, and ended on the date of breast cancer diagnosis, move out of Iowa, death or, if none of these events occurred, on December 31, 2005. The outcome of interest was defined as time from the 1992 questionnaire to the development of breast cancer or censorship.

The association of aspirin and NSAID use with risk of breast cancer was assessed using a Cox proportional hazards regression analysis, modeling age as the time-scale.39 The lowest risk category for each established breast cancer risk factor was modeled as the referent category. For analyses of aspirin and NSAIDs, never users were the referent category and hazard ratios (HRs) were assessed for categories of use: ≤1, 2-5, or 6+ per week. Tests for trend were implemented for the frequency of use variables, ordering them from lowest (never) to highest, and including a one degree of freedom linear term in the Cox proportional hazards model. Multivariate analyses for the frequency of use variables included the following variables as covariates: oral contraceptive use (never, ever); use of hormone replacement therapy (never, ever); smoking status (never, former, current); alcohol use (never, former, and current by frequency of use); physical activity level (low, moderate, high); history of rheumatoid arthritis (no, yes); and history of osteoarthritis (no, yes). Covariates were collected from the 1986 and 1992 questionnaires.

Aspirin and NSAID use were examined among all women, as well as within subgroups defined by risk level for each of selected risk factors. We dichotomized these factors into risk categories based on a priori, commonly-defined cutpoints that also ensured adequate sample size to assess aspirin/NSAID associations within each subgroup.

To model the potential clinical impact of prescribing aspirin or NSAID use for specific risk groups, the number needed to treat (NNT) was calculated based on cumulative incidence at 10 years of follow up, using a time-based method, with corresponding 95% confidence intervals.40

All statistical analyses were carried out using SAS (SAS institute, Inc., Cary, NC) and R (R Foundation for Statistical Computing, Vienna, Austria) software systems. All p-values were two-sided, and P<.05 was declared statistically significant.

Results

A total of 26,580 women were included in the analytical cohort, of whom 11,089 (42%) had zero, 10,592 (40%) had one, 4045 (15%) had two, and 854 (3%) had three or more risk factors. Through 2005 (307,178 person-years of follow-up), there were 1581 incident breast cancers. Each of the risk factors was positively associated with an increased risk of breast cancer, although not all were statistically significant (Table 1). The strongest association was observed for women having a family history of breast cancer (HR=1.50; 95% CI 1.30-1.73).

Table 1. Association of Aspirin, Non-Aspirin NSAIDS And Non-Modifiable or Difficult-To-Modify Factors with Risk of Post-Menopausal Breast Cancer, Iowa Women's Health Study, 1992-2005.

Risk Factor N % Cases Person -years HR (95% CI)a HR (95% CI)b
First degree relative with breast cancer
 Negative 22744 88% 1290 263537 1.00 (reference) 1.00 (reference)
 Positive 3122 12% 259 35656 1.48 (1.29, 1.69) 1.50 (1.30, 1.73)
Age at menarche
 11+ years 25506 97% 1518 294879 1.00 (reference) 1.00 (reference)
 <11 years 811 3% 53 9313 1.11 (0.85, 1.46) 1.11 (0.83, 1.50)
Age at menopause
 <55 years 23001 89% 1353 266202 1.00 (reference) 1.00 (reference)
 55+ years 2745 11% 184 31517 1.13 (0.98, 1.33) 1.21 (1.04, 1.45)
Parity/Age at first live birth
 Age at 1st live birth ≤30 y 22829 87% 1344 264613 1.00 (reference) 1.00 (reference)
 Nulliparous or age at 1st live birth >30 y 3460 13% 221 39254 1.10 (0.96, 1.27) 1.10 (0.94, 1.29)
Benign breast disease
 No 21254 80% 1187 245150 1.00 (reference) 1.00 (reference)
 Yes 5182 20% 386 60339 1.33 (1.18, 1.49) 1.29 (1.13, 1.47)
Body mass index
 <30 kg/m2 20557 77% 1175 239158 1.00 (reference) 1.00 (reference)
 30+ kg/m2 6024 23% 406 68021 1.22 (1.09, 1.36) 1.25 (1.10, 1.42)
Aspirin use
 Never 7475 28% 489 84529 1.00 (reference) 1.00 (reference)
 ≤1 / week 8817 33% 535 104210 0.89 (0.79, 1.01) 0.88 (0.77, 1.01)
 2-5 / week 4685 18% 268 55018 0.84 (0.73, 0.98) 0.79 (0.67, 0.94)
 6+ / week 5603 21% 289 63422 0.79 (0.68, 0.91) 0.72 (0.61, 0.84)
P-trend <.001 <.001
NSAID use
 Never 16085 61% 948 185464 1.00 (reference) 1.00 (reference)
 ≤1 / week 4882 18% 275 57750 0.94 (0.82, 1.07) 0.90 (0.78, 1.05)
 2-5 / week 2152 8% 136 25057 1.07 (0.89, 1.28) 1.03 (0.84, 1.26)
 6+ / week 3461 13% 222 38907 1.12 (0.97, 1.29) 1.04 (0.87, 1.23)
P-trend .17 .78
a

Hazard ratios (HR) and 95 confidence intervals (CI), adjusted for age.

b

Each factor in the table is adjusted for age, use of oral contraceptives, use of hormone replacement therapy, smoking, alcohol use, physical activity level, history of rheumatoid arthritis, history of osteoarthritis, and except for the Summary Index, all other risk factors listed in the table.

c

The non-modifiable or difficult-to-modify breast cancer risk factors included family history of breast cancer in a first degree relative, age at menarche <11 years, age at menopause ≥55 years, nulliparous or age at first live birth >30 years, history of benign breast disease, and BMI of ≥30 kg/m2.

As a main effect, aspirin use was inversely associated with breast cancer risk after multivariate adjustment (HR=0.72 for use 6+ times/week versus never use; 95% CI 0.61-0.84; P-trend<.001), while there was no association for other (non-aspirin) NSAIDs at the same frequency of use (HR=1.04; 95% CI 0.87-1.23; P-trend=.78) (Table 1).

We next evaluated the association of aspirin use with breast cancer risk for each of the selected risk factors, adjusted for other breast cancer risk factors and for each other (Table 2 and Figure 1). Aspirin use was inversely associated with risk of breast cancer for women in both risk categories of family history of breast cancer and history of benign breast disease. Specifically, aspirin use was associated with a lower risk of breast cancer for women with (HR=0.62 for 6+ per week vs. never use; 95% CI 0.41-0.93) and without (HR=0.73; 95% CI 0.61-0.88) a family history of breast cancer, and for women with (HR=0.69; 95% CI 0.50-0.95) and without (HR=0.72; 95% CI 0.60-0.87) a history of benign breast disease. For age at menarche, aspirin use was only associated with a lower risk of breast cancer for women with an age of menarche age 11 years and older (HR=0.70; 95% CI 0.59-0.83) but not for higher risk women with an age at menarche for age <11 years (HR=1.14; 95% CI 0.49-2.62). For age at menopause and parity/age at first live birth, inverse associations of aspirin use with breast cancer risk was observed in both risk groups, but were only statistically significant in the lower risk subgroups (i.e., age at menopause <55 years and parity/age at first live birth 1+/≤30 years). Finally, for BMI, the inverse association with aspirin use was only observed for lower risk women with a BMI <30 kg/m2 (HR=0.62; 95% CI 0.51-0.75) but not for the women with a BMI of 30+ (HR=0.98; 95% CI 0.73-1.32).

Table 2. Association of Aspirin Use with Risk of Post-Menopausal Breast Cancer for Subgroups Defined By Individual Risk Factors, Iowa Women's Health Study 1992-2005a.

Use of Aspirin

Subgroup Never ≤1 / week 2-5/week 6+/week P-trend
First degree relative with breast cancer
 Negative Cases / p-years 396 / 72492 439 / 89744 215 / 47012 240 / 54288
HR (95% CI) 1.00 (reference) 0.89 (0.77, 1.03) 0.78 (0.65, 0.94) 0.73 (0.61, 0.88) <.001
 Positive Cases / p-years 85 / 9543 83 / 11986 45 / 6443 46 / 7683
HR (95% CI) 1.00 (reference) 0.82 (0.59, 1.14) 0.84 (0.57, 1.24) 0.62 (0.41, 0.93) .029
Age at menarche
 11+ years Cases / p-years 472 / 81000 513 / 100705 260 / 52514 273 / 60660
HR (95% CI) 1.00 (reference) 0.87 (0.76, 0.99) 0.79 (0.67, 0.94) 0.70 (0.59, 0.83) <.001
 <11 years Cases / p-years 12 / 2764 19 / 2610 7 / 1826 15 / 2112
HR (95% CI) 1.00 (reference) 1.52 (0.71, 3.25) 0.79 (0.29, 2.13) 1.14 (0.49, 2.62) .90
Age at menopause
 <55 years Cases / p-years 424 / 73159 452 / 89964 226 / 47270 251 / 55809
HR (95% CI) 1.00 (reference) 0.89 (0.77, 1.02) 0.79 (0.66, 0.94) 0.70 (0.59, 0.83) <.001
 55+ years Cases / p-years 56 / 8653 66 / 11042 31 / 5923 31 / 5899
HR (95% CI) 1.00 (reference) 0.84 (0.57, 1.23) 0.82 (0.52, 1.31) 0.82 (0.52, 1.30) .38
Parity/Age at first live birth
 1+/≤30 years Cases / p-years 417 / 72193 444 / 89485 236 / 48228 247 / 54706
HR (95% CI) 1.00 (reference) 0.85 (0.74, 0.99) 0.80 (0.67, 0.95) 0.71 (0.59, 0.84) <.001
 0/>30 years Cases / p-years 69 / 11462 82 / 13667 30 / 6154 40 / 7971
HR (95% CI) 1.00 (reference) 1.07 (0.75, 1.52) 0.73 (0.44, 1.20) 0.76 (0.48, 1.19) .11
Benign breast disease
 No Cases / p-years 367 / 68162 400 / 83408 211 / 43971 209 / 49609
HR (95% CI) 1.00 (reference) 0.90 (0.77, 1.05) 0.87 (0.72, 1.05) 0.72 (0.60, 0.87) .001
 Yes Cases / p-years 118 / 15858 135 / 20380 55 / 10650 78 / 13451
HR (95% CI) 1.00 (reference) 0.83 (0.63, 1.08) 0.57 (0.40, 0.82) 0.69 (0.50, 0.95) .004
Body mass index
 <30 kg/m2 Cases / p-years 366 / 63464 412 / 84158 204 / 43806 193 / 47730
HR (95% CI) 1.00 (reference) 0.83 (0.71, 0.97) 0.75 (0.62, 0.91) 0.62 (0.51, 0.75) <.001
 ≥30 kg/m2 Cases / p-years 123 / 21065 123 / 20052 64 / 11212 96 / 15692
HR (95% CI) 1.00 (reference) 1.02 (0.77, 1.33) 0.94 (0.67, 1.31) 0.98 (0.73, 1.32) .81
a

Adjusted for age, use of oral contraceptives, use of hormone replacement therapy, smoking, alcohol use, physical activity level, history of rheumatoid arthritis, history of osteoarthritis all other factors in the table.

Figure 1. Association of aspirin use with risk of post-menopausal breast cancer risk for subgroups defined by individual risk factors, Iowa Women's Health Study 1992-2005.

Figure 1

There were no associations for use of other NSAIDs with breast cancer risk for any of the subgroups defined in Table 2 (data not shown).

Given that only family history of breast cancer and benign breast disease had statistically significant inverse associations for aspirin use in the higher risk groups (i.e., family history positive or history of benign breast disease), one could argue that the risk-benefit ratio for using aspirin chemoprevention might be more favorable for these women. To better quantify this strategy, we calculated the number needed to treat (NNT) with 6+ aspirin per week to prevent one additional breast cancer in 10 years of follow-up. For women with a negative family history the NNT was 83 (95% CI 49-282), but among women with a positive family history the NNT was substantially lower at 38 (95% CI 19-∞). The NNT among women with no history of benign breast disease was 83 (95% CI 48-305), while for women with a history of benign breast disease the NNT was 40 (95% CI 22-192). These estimates would need to be balanced against the absolute risks for the negative outcomes of regular aspirin use over 10 years, which was not available from our study.

Discussion

To understand the potential risk/benefit ratio for targeted chemoprevention using aspirin or other NSAIDs, we characterized the association of aspirin use with breast cancer in higher risk groups of postmenopausal women defined by non-modifiable or difficult-to-modify risk factors. We found regular aspirin use, but not other NSAIDs, was inversely associated with breast cancer incidence for postmenopausal women at higher risk as defined by a positive family history of breast cancer or a history of benign breast disease. In contrast, use of aspirin or other NSAIDs was not protective among women at higher risk as defined by age at menarche and body mass index, and to a lesser extent parity/age of first live birth and age at menopause. This may have implications for mechanistic pathways that aspirin chemoprevention targets, as well as clinical implications for the design of future trials and clinical management. For example, our analysis found that the NNT to prevent one additional breast cancer among women with a positive family history or with a personal history of benign breast disease is about one-half the NNT for those without such a history, perhaps changing the risk/benefit balance for aspirin chemoprevention in this setting.

This study adds to the literature by investigating the effect of aspirin on breast cancer risk among higher risk subgroups of women, namely postmenopausal women with non-modifiable or difficult-to-modify breast cancer risk factors. Its strengths include the prospective cohort design, ascertainment of cancer incidence using high-quality SEER cancer registry data, virtually complete follow-up for mortality, and availability of information on multiple risk and protective factors to evaluate potential confounding. The study was population-based, which enhances its external validity.

This study also has limitations. Our questionnaire did not assess the type, dose, or duration of aspirin or non-aspirin NSAID use, although we were able to distinguish between use of two major classes of agents and ascertain frequency of use. The majority of the population was Caucasian, and these associations may vary among other racial and ethnic groups. The observational study design has the potential for lower internal validity than an experimental (i.e., randomized controlled trial) design would have, particularly with respect to potential bias due to self-selection and confounding. However, we did adjust for multiple known confounders, although there may be residual confounding or other unknown confounders. Finally, while all of the a priori defined risk factors were positively associated with a higher risk of breast cancer in our cohort, not all were statistically significant. Similarly, small numbers in some of the higher risk subgroups resulted in limited power to identify subgroup effects and may have contributed to the observed null associations.

A majority,15-24,26 but not all,27,28,41,42 studies have reported an inverse association of aspirin with post-menopausal breast cancer. In a meta-analysis of 33 studies (19 cohort studies, 13 case-control studies, and 1 randomized controlled trial [RCT]) that included 1,916,448 subjects, aspirin use was found to be associated with a 14% lower risk of breast cancer (OR=0.86; 95% CI 0.81-0.92).43 Similar to our study, multiple studies have also suggested that a higher frequency (daily) and duration (>5 years) of aspirin use is associated with lower risk of breast cancer.20-22,24,26 However, in the meta-analysis, cohort studies also showed a slightly weaker effect (OR=0.91; 95% CI 0.84-0.98) and there was substantial heterogeneity (I2=80.5%), which could be due to differences in study populations, exposure measurement, and adjustment factors or perhaps differences in the prevalence in risk factors in the study population, given our findings of differential effects of aspirin across some breast cancer risk factors. In the only randomized study, the Women's Health Study trial44 did not find a protective effect of aspirin (RR=0.98; 95% CI 0.89-1.08) suggesting lack of efficacy and bias in observational studies, although the lack of association might be due to the lower frequency (alternate day aspirin use) and low dose of aspirin (100 mg) used in the trial.

There has been much less assessment of the association of aspirin and breast cancer risk by other risk factors that are largely non-modifiable in post-menopausal women, and this is one of the first studies to compressively look into this issue. However, studies have reported reduced risk of breast cancer recurrence and improved survival among breast cancer survivors with aspirin use or combined aspirin and NSAID use.45,46 In a prospective observational study based on the Nurses' Health Study, aspirin use was associated with a decreased risk of breast cancer recurrence (RR=0.57 for aspirin use 6-7 times/week versus no use; 95% CI 0.39-0.82) and death (RR=0.36 for aspirin use 6-7 times/week versus no use; 95% CI 0.24-0.54), suggesting a potential role of aspirin in the secondary prevention of breast cancer.45 Similarly, a recent meta-analysis showed that ASA and NSAID use after but not before breast cancer diagnosis was associated with improved breast cancer survival.47 Given our finding that aspirin was associated with reduced breast cancer risk in all lower risk subgroups, future studies should explore the potential chemopreventive effect of aspirin on breast cancer recurrence among women with lower risk profiles.

Aspirin use was inversely associated with risk among women with a family history of breast cancer or a personal history of benign breast disease, factors predominantly associated with increased risk of both estrogen receptor positive and negative breast cancer, but not among women in the higher risk groups for early age at menarche or high BMI, factors predominantly associated with increased risk of estrogen receptor positive breast cancer.35,48 These results raise the hypothesis that the association of aspirin with reduced breast cancer may not be directly related to estrogen receptor mediated signaling pathways but may be through other pathways, such as cyclooxygenase pathway,49 phosphatidylinositol 3-kinase downregulation,50 B-cell lymphoma 2 mediated apoptosis,51 or epidermal growth factor receptor inhibition, and p53 acetylation.52 It is also possible that certain risk factors that induce chronic inflammation to various degrees (e.g., obesity or smoking), alone or on combination, may create a threshold above which anti-inflammatory drugs such as aspirin at standard doses fail to provide benefit. In such a scenario, a higher dose of aspirin may be required, which would increase the risk of adverse events. This could be addressed by analogs of aspirin chemically modified to have reduced gastrointestinal toxicity, which have shown promising results for breast cancer inhibition in animal models.52 Additional in vivo and in vitro studies are needed to further elucidate the biological mechanisms underlying the association of aspirin with reduced breast cancer risk among women with lower levels of hormone exposure.

Consistent with our prior observations in the IWHS cohort,38 and those of others,20,21,30 but not all,23,24 non-aspirin NSAID use was not associated with breast cancer incidence. The observed differences between aspirin and NSAIDs could be due to the additional biologic effects of aspirin, such as the irreversible inhibition of COX enzymes (as compared to reversible inhibition by non-aspirin NSAIDs) or the potential cancer-preventive effects from inhibition of platelet activation (not seen with non-aspirin NSAIDs).7 In addition, the heterogeneity in the literature could be due to greater variability in the dose, type, and duration of non-aspirin NSAID use. Indeed a meta-analysis of epidemiological studies,53 reported that the inverse association between non-aspirin NSAIDs and breast cancer was weaker than that of aspirin, and there was significant heterogeneity in the results based on study design, population studied, and exposure assessment for the non-aspirin NSAIDs.

Our results could have important implications for designing clinical trials of aspirin chemoprevention by focusing on higher risk women given the need to maximize the risk/benefit profile. Our study suggests that women with a family history of breast cancer or a personal history of benign breast disease might be targeted, although this concept needs confirmation in other studies. Ideally, a randomized controlled clinical trial needs to be conducted to confirm the epidemiological findings before aspirin can be recommended for clinical use. Given the negative results of the Women's Health Study44 and other large chemoprevention studies,54-57 it is unlikely that a large randomized trial assessing general chemopreventive effects of aspirin would be conducted in the near future among unselected women.7,58,59 Instead, targeted chemoprevention in selected populations based on individual risk profile and other risk biomarkers should be pursued.60,61 For example, findings from a cohort study have suggested that aspirin may reduce the risk of progression to breast carcinoma among women with benign breast disease and the association might vary with COX-2 polymorphisms.49

Conclusion

Our results raise the hypothesis that aspirin chemoprevention may only be effective in certain higher risk groups and not others, which may provide insight into mechanistic pathways underlying these observations and also would have implications for the design of trials to target higher risk women. Additional work in this area is warranted.

Acknowledgments

We thank Sondra Buehler for editorial assistance.

Grant Support: This work was supported by a grant from the National Institutes of Health (R01 CA39742).

Abbreviations and Acronyms

NSAIDs

non-steroidal anti-inflammatory drugs

Cox

cyclooxygenase

BMI

body mass index

IWHS

Iowa Women's Health Study

NNT

number needed to treat

OR

odds ratio

RR

relative risk

Footnotes

Potential competing Interests: None.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • 1.Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–1314. doi: 10.1002/cncr.28509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.National Cancer Institute. SEER Stat Fact Sheets: Breast Cancer Statistics. http://seer.cancer.gov/statfacts/html/breast.html.
  • 3.Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146(5):376–389. doi: 10.7326/0003-4819-146-5-200703060-00010. [DOI] [PubMed] [Google Scholar]
  • 4.Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23(6):1403–1415. doi: 10.1093/annonc/mds113. [DOI] [PubMed] [Google Scholar]
  • 5.Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review) Oncol Rep. 2005;13(4):559–583. [PubMed] [Google Scholar]
  • 6.Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501–507. doi: 10.1016/S1470-2045(09)70035-X. [DOI] [PubMed] [Google Scholar]
  • 7.Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nature Rev Clin Oncol. 2012;9:259–267. doi: 10.1038/nrclinonc.2011.199. [DOI] [PubMed] [Google Scholar]
  • 8.Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602–1612. doi: 10.1016/S0140-6736(11)61720-0. [DOI] [PubMed] [Google Scholar]
  • 9.Hial V, Horakova Z, Shaff FE, Beaven MA. Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. Eur J Pharmacol. 1976;37(2):367–376. doi: 10.1016/0014-2999(76)90044-3. [DOI] [PubMed] [Google Scholar]
  • 10.Bennett A, Curwain BP. Effects of aspirin-like drugs on canine gastric mucosal blood flow and acid secretion. Br J Pharmacol. 1977;60(4):499–504. doi: 10.1111/j.1476-5381.1977.tb07527.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Karmali RA, Welt S, Thaler HT, Lefevre F. Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br J Cancer. 1983;48(5):689–696. doi: 10.1038/bjc.1983.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Watson J, Chuah SY. Prostaglandins, steroids and human mammary cancer. Eur J Cancer Clin Oncol. 1985;21(9):1051–1055. doi: 10.1016/0277-5379(85)90290-1. [DOI] [PubMed] [Google Scholar]
  • 13.Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005;23(2):254–266. doi: 10.1200/JCO.2005.09.112. [DOI] [PubMed] [Google Scholar]
  • 14.Su B, Diaz-Cruz ES, Landini S, Brueggemeier RW. Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids. 2008;73(1):104–111. doi: 10.1016/j.steroids.2007.09.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5(2):138–146. doi: 10.1097/00001648-199403000-00003. [DOI] [PubMed] [Google Scholar]
  • 16.Harris RE, Namboodiri K, Stellman SD, Wynder EL. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med. 1995;24(2):119–120. doi: 10.1006/pmed.1995.1022. [DOI] [PubMed] [Google Scholar]
  • 17.Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 1996;7(2):203–205. doi: 10.1097/00001648-199603000-00017. [DOI] [PubMed] [Google Scholar]
  • 18.Coogan PF, Rao SR, Rosenberg L, et al. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med. 1999;29(2):72–76. doi: 10.1006/pmed.1999.0518. [DOI] [PubMed] [Google Scholar]
  • 19.Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer. 2000;83(1):112–120. doi: 10.1054/bjoc.2000.1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004;291(20):2433–2440. doi: 10.1001/jama.291.20.2433. [DOI] [PubMed] [Google Scholar]
  • 21.Marshall SF, Bernstein L, Anton-Culver H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst. 2005;97(11):805–812. doi: 10.1093/jnci/dji140. [DOI] [PubMed] [Google Scholar]
  • 22.Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer. 2005;5:159. doi: 10.1186/1471-2407-5-159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol. 2005;162(2):165–170. doi: 10.1093/aje/kwi182. [DOI] [PubMed] [Google Scholar]
  • 24.Kirsh VA, Kreiger N, Cotterchio M, Sloan M, Theis B. Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol. 2007;166(6):709–716. doi: 10.1093/aje/kwm216. [DOI] [PubMed] [Google Scholar]
  • 25.Ready A, Velicer CM, McTiernan A, White E. NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat. 2008;109(3):533–543. doi: 10.1007/s10549-007-9665-x. [DOI] [PubMed] [Google Scholar]
  • 26.Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003;63(18):6096–6101. [PubMed] [Google Scholar]
  • 27.Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst. 1996;88(14):988–993. doi: 10.1093/jnci/88.14.988. [DOI] [PubMed] [Google Scholar]
  • 28.Jacobs EJ, Thun MJ, Connell CJ, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(1):261–264. [PubMed] [Google Scholar]
  • 29.Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol. 2007;166(10):1150–1158. doi: 10.1093/aje/kwm195. [DOI] [PubMed] [Google Scholar]
  • 30.Gierach GL, Lacey JV, Jr, Schatzkin A, et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res. 2008;10(2):R38. doi: 10.1186/bcr2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of post-menopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:1586–1591. [PubMed] [Google Scholar]
  • 32.Hortobagyi GN, Brown PH. Two good choices to prevent breast cancer: great taste, less filling. Cancer Prev Res (Phila) 2010;3(6):681–685. doi: 10.1158/1940-6207.CAPR-10-0101. [DOI] [PubMed] [Google Scholar]
  • 33.Folsom AR, Kaye SA, Prineas RJ, Potter JD, Gapstur SM, Wallace RB. Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol. 1990;131(5):794–803. doi: 10.1093/oxfordjournals.aje.a115570. [DOI] [PubMed] [Google Scholar]
  • 34.Bisgard KM, Folsom AR, Hong CP, Sellers TA. Mortality and cancer rates in nonrespondents to a prospective cohort study of older women: 5-year follow-up. Am J Epidemiol. 1994;139(10):990–1000. doi: 10.1093/oxfordjournals.aje.a116948. [DOI] [PubMed] [Google Scholar]
  • 35.Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250–263. doi: 10.1093/jnci/djq526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–1886. doi: 10.1093/jnci/81.24.1879. [DOI] [PubMed] [Google Scholar]
  • 37.Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. National Cancer Institute; Bethesda, MD: 2008. http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site. [Google Scholar]
  • 38.Bardia A, Olson JE, Vachon CM, et al. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat. 2011;126(1):149–155. doi: 10.1007/s10549-010-1074-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145(1):72–80. doi: 10.1093/oxfordjournals.aje.a009034. [DOI] [PubMed] [Google Scholar]
  • 40.Suissa D, Brassard P, Smiechowski B, Suissa S. Number needed to treat is incorrect without proper time-related considerations. J Clin Epidemiol. 2012;65(1):42–46. doi: 10.1016/j.jclinepi.2011.04.009. [DOI] [PubMed] [Google Scholar]
  • 41.Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol. 2012;30(28):3468–3477. doi: 10.1200/JCO.2012.42.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000;320(7250):1642–1646. doi: 10.1136/bmj.320.7250.1642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Luo T, Yan HM, He P, Luo Y, Yang YF, Zheng H. Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2012;131(2):581–587. doi: 10.1007/s10549-011-1747-0. [DOI] [PubMed] [Google Scholar]
  • 44.Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294(1):47–55. doi: 10.1001/jama.294.1.47. [DOI] [PubMed] [Google Scholar]
  • 45.Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28(9):1467–1472. doi: 10.1200/JCO.2009.22.7918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Blair CK, Sweeney C, Anderson KE, Folsom AR. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat. 2007;101(2):191–197. doi: 10.1007/s10549-006-9277-x. [DOI] [PubMed] [Google Scholar]
  • 47.Zhong S, Zhang X, Chen L, Ma T, Tang J, Zhao J. Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies. Breast Cancer Res Treat. 2015;150(1):199–207. doi: 10.1007/s10549-015-3300-z. [DOI] [PubMed] [Google Scholar]
  • 48.Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004;96(3):218–228. doi: 10.1093/jnci/djh025. [DOI] [PubMed] [Google Scholar]
  • 49.Gallicchio L, McSorley MA, Newschaffer CJ, et al. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer. 2006;106(7):1443–1452. doi: 10.1002/cncr.21763. [DOI] [PubMed] [Google Scholar]
  • 50.Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596–1606. doi: 10.1056/NEJMoa1207756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Choi BH, Chakraborty G, Baek K, Yoon HS. Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells. Exp Mol Med. 2013;45:e47. doi: 10.1038/emm.2013.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Huang L, Wong CC, Mackenzie GG, et al. Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress. BMC Cancer. 2014;14:141. doi: 10.1186/1471-2407-14-141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer. 2003;3:28. doi: 10.1186/1471-2407-3-28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.ATBC Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330:1029–1035. doi: 10.1056/NEJM199404143301501. [DOI] [PubMed] [Google Scholar]
  • 55.Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293(11):1338–1347. doi: 10.1001/jama.293.11.1338. [DOI] [PubMed] [Google Scholar]
  • 56.Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA. 2009;301(1):39–51. doi: 10.1001/jama.2008.864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2009;301(1):52–62. doi: 10.1001/jama.2008.862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Brewster AM, Patterson SL, Forman MR, et al. Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res (Phila) 2010;3(8):1044–1048. doi: 10.1158/1940-6207.CAPR-10-0141. [DOI] [PubMed] [Google Scholar]
  • 59.Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12(5):496–503. doi: 10.1016/S1470-2045(11)70030-4. [DOI] [PubMed] [Google Scholar]
  • 60.Arun B, Dunn BK, Ford LG, Ryan A. Breast cancer prevention trials: large and small trials. Semin Oncol. 2010;37(4):367–383. doi: 10.1053/j.seminoncol.2010.05.004. [DOI] [PubMed] [Google Scholar]
  • 61.Uray IP, Brown PH. Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res. 2011;188:147–162. doi: 10.1007/978-3-642-10858-7_13. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES